

PRODUCT DESCRIPTION:

A mouse IgG_{2a} monoclonal antibody directed against human CD45RO cell surface antigen. Purified from hybridoma culture supernatant by affinity chromatography and conjugated to ϵ -amino caproyl biotin. Anti-human CD45RO biotin is designed to be used with Anti-Biotin Tetrameric Antibody Complexes (TAC) during StemSep[®] or EasySep[®] magnetic cell separation. Anti-Biotin TAC contains a combination of mouse and rat monoclonal antibodies purified from hybridoma culture supernatant by affinity chromatography. These antibodies are bound in bispecific TAC, which are directed against biotin and dextran.

SPECIFICITY:

Anti-CD45RO antibody binds to an isoform of the leukocyte common antigen. The CD45RO antigen is found on memory and activated T cells, B cell subsets, monocytes and granulocytes.

FORMAT:

Catalog #14556 contains:

- 1 x 14556C – Biotinylated Anti-Human CD45RO
- 1 x 13050 – StemSep[®] Anti-Biotin TAC

Catalog #14566 contains:

- 5 x 14556C
- 5 x 13050

Biotinylated Anti-Human CD45RO antibody (#14556C) is supplied at a concentration of **200 µg/mL** in phosphate buffered saline containing <0.1% (w/v) sodium azide and 0.1% BSA.

It should be kept in mind that this product is a biological reagent, and as such cannot be completely characterized or quantified. Some variability is unavoidable.

STABILITY AND STORAGE:

Store at 2 - 8°C. Do not freeze. Stable for 2 years. Contents sterile in unopened tube.

APPLICATIONS:

Deplete CD45RO⁺ cells from human peripheral blood mononuclear cell samples by combining CD45RO biotinylated antibody and Anti-Biotin TAC with StemSep[®] or EasySep[®] magnetic cell separation.

**THIS REAGENT IS FOR RESEARCH ONLY.
IT IS NOT TO BE ADMINISTERED TO HUMANS.**

Hazardous Ingredient: Sodium Azide. Avoid exposure to skin and eyes, ingestion, and contact with heat, acids and metals. Wash exposed skin with soap and water. Flush eyes with water. Dilute with running water before discharging into plumbing.

StemCell Technologies

In North America
Tel: 1.604.877.0713
Fax: 1.604.877.0704
Toll Free Tel: 1.800.667.0322
Toll Free Fax: 1.800.567.2899
e-mail: info@stemcell.com
www.stemcell.com

In the United Kingdom
Tel: +44.(0).20.7537.7565
Fax: +44.(0).20.7515.5408
Toll Free within United Kingdom:
Tel: 0800.731.27.14
Fax: 0800.731.27.13
e-mail: info@stemcellgb.com

In Europe
Tel: +33.(0).4.76.04.75.30
Fax: +33.(0).4.76.18.99.63
e-mail: info@stemcellfrance.com

Revised:
November 2006

Product Information Sheet



Version 2.0.0

ANTI-HUMAN CD45RO BIOTIN

with
Anti-Biotin Tetrameric
Antibody Complex

Catalog #14556
Catalog #14566

300 µL
1.5 mL

To isolate naïve human CD8⁺ T cells:

Add CD45RO biotinylated antibody and Anti-Biotin TAC with either **StemSep[®] CD8⁺ T Cell Enrichment** cocktail (Catalog #14053) or **EasySep[®] CD8⁺ T Cell Enrichment** cocktail (Catalog #19053).

DIRECTIONS FOR USE:

Centrifuge tube before using to ensure recovery of entire contents.

Add antibody at 20 µL/mL of cells prepared at a concentration of 5×10^7 cells/mL. Titration may be required for optimal performance. Wash cells and resuspend at 5×10^7 cells/mL in recommended medium. Add 100 µL of Anti-Biotin TAC per mL of cells. When adding TAC with an enrichment cocktail, add the TAC during the same step as adding the cocktail to the cells. Mix well and proceed with standard enrichment protocol.

See accompanying 13050 Product Information Sheet for more information

Please contact us for further protocol information if required.

Refer to Material Safety Data Sheet for more information.

REFERENCES:

1. Lansdorp PM, Aalberse RC, Bos R, Schutter W and Van Bruggen EFJ. Cyclic tetramolecular complexes of monoclonal antibodies: A new type of cross-linking reagent. Eur. J. Immunol. 1986; 16: 679.
2. Thomas TE, Sutherland HJ and Lansdorp PM. Specific binding and release of cells from beads using cleavable tetrameric antibody complexes. J. Immunol. Methods 1989; 120: 221.
3. Chun T-W, Engel D, Berrey MM, Shea T, Corey L, Fauci AS: Early establishment of a pool of latently infected, resting CD4⁺ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: